alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
II 

111TH CONGRESS 

1ST SESSION S. 2526 

To extend and modify the temporary suspension of duty on certain women’s 

footwear, valued over $23/pair, covering the ankle, whose height from 

the bottom of the outer sole to the top of the upper does not exceed 

8 inches, with a coated or laminated textile fabric. 

IN THE SENATE OF THE UNITED STATES 

OCTOBER 30, 2009 

Ms. CANTWELL introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To extend and modify the temporary suspension of duty 

on certain women’s footwear, valued over $23/pair, covering the ankle, whose height from the bottom of the 

outer sole to the top of the upper does not exceed 8 

inches, with a coated or laminated textile fabric. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


smartinez on DSKB9S0YB1PROD with BILLS
2 

•S 2526 IS

1 SECTION 1. CERTAIN WOMEN’S FOOTWEAR, VALUED OVER 

2 $23/PAIR, COVERING THE ANKLE, WHOSE 

3 HEIGHT FROM THE BOTTOM OF THE OUTER 

4 SOLE TO THE TOP OF THE UPPER DOES NOT 

5 EXCEED 8 INCHES, WITH A COATED OR LAMI6 NATED TEXTILE FABRIC. 

7 (a) IN GENERAL.—Heading 9902.23.82 of the Har8 monized Tariff Schedule of the United States (relating to 

9 certain women’s footwear, valued over $23/pair, covering 

10 the ankle, whose height from the bottom of the outer sole 

11 to the top of the upper does not exceed 8 inches, with 

12 a coated or laminated textile fabric) is amended— 

13 (1) by striking ‘‘$20/pair’’ and inserting ‘‘$23/ 

14 pair’’; and 

15 (2) by striking the date in the effective column 

16 period and inserting ‘‘12/31/2011’’. 

17 (b) EFFECTIVE DATE.—The amendment made by 

18 subsection (a) applies to goods entered, or withdrawn from 

19 warehouse for consumption, on or after the 15th day after 

20 the date of the enactment of this Act. 

Æ 


smartinez on DSKB9S0YB1PROD with BILLS
Exhibit 21.1

Subsidiaries of Plains Exploration & Production Company



|                                |  |                             
|------------------------------- |  | ----------------------------
|Name of Subsidiary              |  | Jurisdiction of Organization
|Arguello Inc.                   |  | Delaware                    
|Arroyo Grande Land Company LLC  |  | Delaware                    
|Cane River Development LLC      |  | Delaware                    
|Latigo Petroleum, Inc.          |  | Delaware                    
|Lompoc Land Company LLC         |  | Delaware                    
|Montebello Land Company LLC     |  | Delaware                    
|Nuevo Energy Company            |  | Delaware                    
|Plains Acquisition Corporation  |  | Delaware                    
|Plains Offshore Inc.            |  | Delaware                    
|Plains Offshore Operations Inc. |  | Delaware                    
|Plains Resources Inc.           |  | Delaware                    
|Plains Vietnam Ltd.             |  | Cayman Islands              
|Pogo Alberta, ULC               |  | Canada                      
|Pogo Finance, ULC               |  | Canada                      
|Pogo New Zealand Holdings, LLC  |  | Delaware                    
|Pogo Partners, Inc.             |  | Texas                       
|Pogo Producing Company LLC      |  | Delaware                    
|PXP Aircraft LLC                |  | Delaware                    
|PXP Gulf Coast LLC              |  | Delaware                    
|PXP Louisiana L.L.C.            |  | Delaware                    
|PXP Louisiana Operations LLC    |  | Delaware                    
|PXP Resources LLC               |  | Delaware
[Federal Register Volume 74, Number 24 (Friday, February 6, 2009)]
[Notices]
[Page 6311]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-2538]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated October 7, 2008 and published in the Federal 
Register on October 14, 2008, (73 FR 60719), Halo Pharmaceutical Inc., 
30 North Jefferson Road, Whippany, New Jersey 07981, made application 
to the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydromorphine (9145).....................  I
Hydromorphone (9150).......................  II
------------------------------------------------------------------------

    Dihydromorphine is an intermediate in the manufacture of 
Hydromorphone and is not for commercial distribution. The company plans 
to manufacture Hydromorphone HCL for sale to other manufacturers and 
for the manufacture of other controlled substance dosage units for 
distribution to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Halo Pharmaceutical Inc. to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated Halo Pharmaceutical Inc. to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33, the above named company is granted registration as a 
bulk manufacturer of the basic classes of controlled substances listed.

    Dated: January 30, 2009.
 Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-2538 Filed 2-5-09; 8:45 am]
BILLING CODE 4410-09-P
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE AUDITED
BALANCE SHEET AS OF JANUARY 29, 2000 AND AUDITED STATEMENT OF OPERATIONS FOR THE
YEAR THEN ENDED AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH ANNUAL
REPORT ON FORM 10-K FOR THE YEAR ENDED JANUARY 29, 2000.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JAN-29-2000
<PERIOD-START>                             JAN-30-1999
<PERIOD-END>                               JAN-29-2000
<CASH>                                           2,480
<SECURITIES>                                         0
<RECEIVABLES>                                    2,382
<ALLOWANCES>                                         0
<INVENTORY>                                      9,585
<CURRENT-ASSETS>                                16,259
<PP&E>                                          28,659
<DEPRECIATION>                                (16,041)
<TOTAL-ASSETS>                                  28,877
<CURRENT-LIABILITIES>                            6,118
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        98,693
<OTHER-SE>                                    (95,956)
<TOTAL-LIABILITY-AND-EQUITY>                    28,877
<SALES>                                         69,884
<TOTAL-REVENUES>                                69,884
<CGS>                                           45,330
<TOTAL-COSTS>                                   31,238
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                 9,982
<INTEREST-EXPENSE>                                 219
<INCOME-PRETAX>                               (18,285)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (18,285)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (18,285)
<EPS-BASIC>                                   (2.59)
<EPS-DILUTED>                                   (2.59)


</TABLE>
<PAGE>

                                                                    EXHIBIT 32.1

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                       AS ADOPTED PURSUANT TO SECTION 906
                        OF THE SARBANES-OXLEY ACT OF 2002

      In connection with the Quarterly Report of Wolverine Tube, Inc. (the
"Company") on Form 10-Q for the period ending July 3, 2005 as filed with the
Securities and Exchange Commission (the "Report"), I, Dennis J. Horowitz, Chief
Executive Officer of Wolverine Tube, Inc., certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that to the best of my knowledge and belief:

      (1)   The Report fully complies with the requirements of Section 13(a) or
            15(d) of the Securities Exchange Act of 1934; and

      (2)   The information contained in the Report fairly presents, in all
            material respects, the financial condition and results of operations
            of the Company.

      A signed original of this written statement required by Section 906 has
been provided to Wolverine Tube, Inc. and will be retained by Wolverine Tube,
Inc. and furnished to the Securities and Exchange Commission or its staff upon
request.

/s/ Dennis J. Horowitz

Dennis J. Horowitz
Chief Executive Officer
August 12, 2005
CERTIFICATION OF CHIEF FINANCIAL OFFICER
                          OF CORPORATE GENERAL PARTNER

            PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The  undersigned,  Robert A. Bourne,  the  President and Treasurer of CNL Realty
Corporation,  the corporate  general  partner of CNL Income Fund XIII, Ltd. (the
"Partnership"),  has executed this  certification  in connection with the filing
with the Securities and Exchange  Commission of the Partnership's  Annual Report
on Form  10-K for the  period  ending  December  31,  2003 (the  "Report").  The
undersigned hereby certifies that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) the  information  contained in the Report fairly  presents,  in all material
respects, the financial condition and results of operations of the Partnership.


Date:  March 24, 2004

                                            /s/ Robert A. Bourne
                                            -----------------------------------
                                            Name:  Robert A. Bourne
                                            Title: President and Treasurer

                                            A signed  original  of this  written
                                            statement  required  by Section  906
                                            has been provided to CNL Income Fund
                                            XIII,  Ltd.  and will be retained by
                                            CNL  Income  Fund  XIII,   Ltd.  and
                                            furnished  to  the   Securities  and
                                            Exchange  Commission  or  its  staff
                                            upon request.
**EXHIBIT 32.2**

# ** **

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with theQuarterly Report on Form 10-Q for the fiscal quarter ended September 30,2005 (the “Report”) by Bentley Pharmaceuticals, Inc. (the “Registrant”),the undersigned hereby certifies that, to his knowledge:

 

1.               TheReport fully complies with the requirements of section 13(a) or 15(d) ofthe Securities Exchange Act of 1934, as amended, and

 

2.               Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Registrant.

 

 
|   | /s/ Michael D.  Price                                             |   |
|--------|-------------------------------------------------------------------|--------|
|   | Michael D. Price                                                  |
|   | Vice President, Chief Financial  Officer, Treasurer and Secretary |
|   | (Principal Financial and Accounting Officer)                      |
|   |                                                              |
|   | November 8,  2005                                            |

 

----
Exhibit 32.1


              CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the fiscal quarter
ended September 30, 2003 (the "Report") by Bentley Pharmaceuticals, Inc. (the
"Registrant"), the undersigned hereby certifies that, to his knowledge:

         1.       The Report fully complies with the requirements of section
                  13(a) or 15(d) of the Securities Exchange Act of 1934, as
                  amended, and

         2.       The information contained in the Report fairly presents, in
                  all material respects, the financial condition and results of
                  operations of the Registrant.




                                                /s/ James R. Murphy
                                                --------------------------------
                                                James R. Murphy
                                                Chairman, President and Chief
                                                Executive Officer
                                                (Chief Executive Officer)
                                                November 14, 2003


A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 HAS BEEN
PROVIDED TO BENTLEY PHARMACEUTICALS, INC. AND WILL BE RETAINED BY BENTLEY
PHARMACEUTICALS, INC., AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION
OR ITS STAFF UPON REQUEST.
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Homeland Security U.S. Customs and Border Protection
 AGENCY: U.S. Customs and Border Protection, U.S. Department of Homeland Security.
 ACTION: General notice.
 SUMMARY: Notice is hereby given that, pursuant to Title 19 of the Code of Federal Regulations at section 111.51(a), the following individual Customs broker licenses and any and all permits have been cancelled due to the death of the broker: Name
License No.
Port nameWilliam C. Cain
03126
Laredo.Robert W. Dugan
11731
New York.Rasa Szepelak
14316
Chicago.
 Dated: May 20, 2009. Daniel Baldwin, Assistant Commissioner, Office of International Trade.


[FR Doc. E9-12426 Filed 5-27-09; 8:45 am] BILLING CODE 9111-14-P
<TABLE> <S> <C>

<ARTICLE>                          5
       
<S>                                <C>
<PERIOD-TYPE>                      6-MOS
<FISCAL-YEAR-END>                  OCT-31-1998
<PERIOD-START>                     NOV-01-1997
<PERIOD-END>                       APR-30-1998
<CASH>                                       3,017,000 
<SECURITIES>                                         0 
<RECEIVABLES>                               35,467,000 
<ALLOWANCES>                                   868,000 
<INVENTORY>                                 33,223,000 
<CURRENT-ASSETS>                            75,027,000 
<PP&E>                                      23,126,000 
<DEPRECIATION>                              10,899,000 
<TOTAL-ASSETS>                              88,899,000 
<CURRENT-LIABILITIES>                       11,195,000 
<BONDS>                                      3,730,000 
<COMMON>                                        15,000 
<PREFERRED-MANDATORY>                                0 
<PREFERRED>                                          0 
<OTHER-SE>                                  72,596,000 
<TOTAL-LIABILITY-AND-EQUITY>                88,899,000 
<SALES>                                     62,083,000 
<TOTAL-REVENUES>                            62,083,000 
<CGS>                                       36,354,000 
<TOTAL-COSTS>                               51,334,000 
<OTHER-EXPENSES>                               280,000 
<LOSS-PROVISION>                               352,000 
<INTEREST-EXPENSE>                             232,000 
<INCOME-PRETAX>                             10,469,000 
<INCOME-TAX>                                 4,090,000 
<INCOME-CONTINUING>                          6,379,000 
<DISCONTINUED>                                       0 
<EXTRAORDINARY>                                      0 
<CHANGES>                                            0 
<NET-INCOME>                                 6,379,000 
<EPS-PRIMARY>                                     0.46 
<EPS-DILUTED>                                     0.43
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Board of Scientific Counselors of the NIH Clinical Center. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the Clinical Center, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         Board of Scientific Counselors of the NIH Clinical Center.                    

*Date:*                         June 18, 2009.                    

*Time:*                         8:15 a.m. to 5:30 p.m.                    

*Agenda:*                         To review and evaluate the Clinical Center's Nursing Department.                    

*Place:*                         National Institutes of Health, Building 10, 10 Center Drive, Room 4-2551, Bethesda, MD 20892.                    

*Contact Person:*                         David K Henderson, MD, Deputy Director for Clinical Care, Office of the Director, Clinical Center, National Institutes of Health, Building 10, Room 6-1480,  Bethesda, MD 20892, (301) 496-3515.                    

Dated: May 26, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-12877 Filed 6-2-09; 8:45 am]

BILLING CODE 4140-01-P
**HR Qualifications Review Checklist for IFPM**

**GS-0401 Fire Management Specialist**
EXHIBIT 11.2

                 COMPUTATION OF FULLY DILUTED EARNINGS PER SHARE


                                                           Years Ended
                                                           September 30,
                                                      --------------------------
                                                         1996            1995
                                                      ----------     -----------
Shares

Weighted average number of common
  shares outstanding                                  11,789,362       9,086,976
Additional shares assuming conversion of:
  Stock Options                                          573,618         600,866
  Warrants                                                39,733         598,562
  Convertible Debentures                                    --           783,642
  Preferred Stock                                        666,667         500,000
                                                     -----------     -----------

Weighted average shares outstanding                   13,069,380      11,570,046
                                                     ===========     ===========

Net Income                                           $ 5,953,295     $ 2,769,849

Add:
  Interest Expense on Convertible
    Debentures (Assuming Conversion)                        --           100,670
  Net income attributable to fully
    diluted weighted average shares
    outstanding                                      $ 5,953,295     $ 2,870,519
                                                     ===========     ===========

Fully Diluted Earnings Per Share                     $      0.46     $      0.25
                                                     ===========     ===========




     All share amounts and per share data have been restated to reflect the
     two-for-one stock split effected as a stock dividend on May 28, 1996.
NOTE: This disposition is nonprecedential.

United States Court of Appeals 

for the Federal Circuit ______________________ 

PATRICIA A. MCCULLEY,

Claimant-Appellant,

v.

Eric K. Shinseki, SECRETARY OF VETERANS 

AFFAIRS,

Respondent-Appellee.

______________________ 

2012-7092

______________________ 

Appeal from the United States Court of Appeals for 

Veterans Claims in No. 10-1362, Judge Robert N. Davis.

______________________ 

JUDGMENT

______________________ 

JOHN B. WELLS, Law Offices of John B. Wells, of 

Slidell, Louisiana, argued for claimant-appellant. 

ALLISON KIDD-MILLER, Trial Attorney, Commercial 

Litigation Branch, Civil Division, United States Department of Justice, of Washington, DC, argued for respondent-appellee. On the brief were STUART F. DELERY, Acting 

Assistant Attorney General, JEANNE E. DAVIDSON, Direc-
 

tor, MARTIN F. HOCKEY, JR., Assistant Director, and 

JAMES SWEET, Trial Attorney. Of counsel on the brief 

were DAVID J. BARRNES, Deputy Assistant General Counsel, and LARA EILHARDT, Staff Attorney, United States 

Department of Veterans Affairs, of Washington, DC.

______________________ 

THIS CAUSE having been heard and considered, it is

ORDERED and ADJUDGED: 

 PER CURIAM (NEWMAN, CLEVENGER, and WALLACH,

Circuit Judges).

AFFIRMED. See Fed. Cir. R. 36.

 ENTERED BY ORDER OF THE COURT

 May 21, 2013 /s/ Jan Horbaly 

 Date Jan Horbaly 

 Clerk
No. 836.

#### Hoblitzelle *v.*City of University Park et al.

See *ante,*p. 781.